Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides

Immune · Research Phase

Beta-Defensin 3

No lawful US pathway

Tell me if this changesRead the free 2026 Peptide Safety Checklist →
Written by Peptide Association Editorial TeamLast reviewed Editorial policy

01 · Overview

Human beta-defensin 3 (hBD-3) is a cationic antimicrobial peptide of roughly 45 amino acids. Unlike hBD-1 and hBD-2, it kills Gram-positive organisms such as Staphylococcus aureus, including multi-resistant strains, in addition to Gram-negative bacteria and yeasts (PMID 15821901).

It also shapes host immune responses, for example by inducing maturation of human skin dendritic cells, which has prompted interest in it as a potential vaccine adjuvant (PMID 22951718).

02 · Research summary & key findings

Laboratory work shows hBD-3 activity against Pseudomonas aeruginosa, Candida albicans, multi-resistant S. aureus, and vancomycin-resistant Enterococcus faecium (PMID 15821901), and it reduced biofilm formation by methicillin-resistant staphylococci on titanium surfaces in vitro (PMID 23273885). Recombinant hBD-3 also inhibited HIV-1 replication in cell culture (PMID 14571200). Evidence remains limited to cell and animal studies; no clinical trials or approved hBD-3 products were found.

03 · Regulatory status

Beta-Defensin 3 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

No lawful pathway today

Beta-Defensin 3 is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding.

See the 1 FDA-approved compound in Immune

Tell me if the status changes

One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.

04 · Administration routes

  • Topical
  • Subcutaneous injection

References

  1. [1]Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication AIDS, 2003. PMID 14571200
  2. [2]Human defensins J Mol Med (Berl), 2005. PMID 15821901
  3. [3]Human beta-defensin 3 induces maturation of human langerhans cell-like dendritic cells: an antimicrobial peptide that functions as an endogenous adjuvant J Invest Dermatol, 2013. PMID 22951718
  4. [4]Human β-defensin 3 inhibits antibiotic-resistant Staphylococcus biofilm formation J Surg Res, 2013. PMID 23273885

Primary literature

Related peptides in Immune

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.